Cardiac Insight

Cardea SOLO™ responds to the unmet need for efficient and affordable diagnosis of a variety of irregular heart rhythms, including atrial fibrillation (AFib). Patient data that was previously routed through multiple clinicians and third-party ECG scanning services can now be delivered in minutes to the prescribing doctor. Cardea SOLO™ is intended to enhance mean time-to-diagnosis and increase savings for patients and health care insurers.

Cardea 20/20 ECG is the only diagnostic device with the International Criteria for ECG interpretation in athletes in its algorithm, enabling physicians to quickly identify difficult-to-diagnose cardiac abnormalities, such as HCM, Long QT and WPW, that put athletes and active youth at risk for sudden cardiac arrest (SCA).

The Cardea SOLO™ Wearable Ambulatory ECG System is prescribed by a medical professional for the detection or assessment of abnormal heart rhythms. Discreetly worn for up to seven days, the Cardea SOLO Sensor or “ECG patch” captures and records every patient heart beat and marks patient-reported symptoms. Comprehensive ECG data is then retrieved and analyzed automatically by sophisticated algorithms, right in the physician office, clinic or research setting, to produce a complete draft summary report in only minutes – no ECG services outsourcing or delays. The Cardea SOLO System includes a comprehensive set of full-disclosure review and analysis tools, and is growing in use as a powerful tool for clinical and scientific heart rhythm research.

Cardea 20/20 ECG™ was designed specifically to help clinicians identify cardiac conditions associated with the risk of sudden cardiac death in active youth and athletes. It’s the only portable diagnostic 12-lead ECG system that incorporates the International Criteria for ECG Interpretation in Young Athletes. Identifying cardiac conditions associated with higher risk of sudden cardiac death in young athletes, from high school to professionals, is becoming an imperative to reduce adverse outcomes. Using Cardea 20/20 ECG’s simple, noninvasive 16-second electrocardiogram (ECG) test is a important and growing part of pre-participation sports exams (PPE), athlete sports physicals, cardiac screening programs as well as routine physicals.

Cardiac Insight is a digital health innovation company in Bellevue, Washington, USA that delivers differentiated solutions used by medical professionals. Our products address challenging (and growing) unmet clinical needs for accurate and cost-effective detection of dangerous cardiac arrhythmias such as atrial fibrillation, and other conditions that can increase the risk of sudden cardiac death, stroke and heart failure. Our medical device systems use automated, advanced ECG analysis algorithms that can help clinicians improve mean time to patient diagnosis and treatment. We leverage point-of-care, Windows PC-based software product platforms to support clinical workflows that keep healthcare professionals at the center of their patient’s care, with focus on patient- and user-friendly design.